876 related articles for article (PubMed ID: 25431993)
1. Monitoring and reversal strategies for new oral anticoagulants.
Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
[TBL] [Abstract][Full Text] [Related]
2. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M; Lip GY
Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
[TBL] [Abstract][Full Text] [Related]
3. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
Enriquez A; Lip GY; Baranchuk A
Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
[TBL] [Abstract][Full Text] [Related]
5. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
6. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
Becattini C; Vedovati MC; Agnelli G
Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
[TBL] [Abstract][Full Text] [Related]
7. Measurement and reversal of the direct oral anticoagulants.
Samuelson BT; Cuker A
Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
9. New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage.
Yasaka M
Front Neurol Neurosci; 2015; 37():93-106. PubMed ID: 26588018
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
Ebright J; Mousa SA
Clin Appl Thromb Hemost; 2015 Mar; 21(2):105-14. PubMed ID: 25115762
[TBL] [Abstract][Full Text] [Related]
11. Management of bleeding in patients receiving non-vitamin K antagonists.
Balla S; Koerber S; Flaker G
Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
[TBL] [Abstract][Full Text] [Related]
12. The new era of anticoagulation.
Skeik N; Rumery KK; Rodriguez GT
Ann Vasc Surg; 2014 Feb; 28(2):503-14. PubMed ID: 24412298
[TBL] [Abstract][Full Text] [Related]
13. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
14. Current state of knowledge on oral anticoagulant reversal using procoagulant factors.
Nitzki-George D; Wozniak I; Caprini JA
Ann Pharmacother; 2013 Jun; 47(6):841-55. PubMed ID: 23695644
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of specific antidotes for target-specific oral anticoagulants.
Mo Y; Yam FK
Pharmacotherapy; 2015 Feb; 35(2):198-207. PubMed ID: 25644580
[TBL] [Abstract][Full Text] [Related]
16. Reversal of dabigatran by idarucizumab: when and how?
Vanassche T; Greinacher A; Verhamme P
Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
18. Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.
Chan NC; Bhagirath V; Dale BJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2015 Nov; 13(11):1213-23. PubMed ID: 26471327
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants: new drugs and new concepts.
Levy JH; Spyropoulos AC; Samama CM; Douketis J
JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
